What is bisabolol—and is it the same as levomenol?

Alpha-bisabolol belongs to the sesquiterpene alcohols, a group of plant compounds with 15 carbon atoms and an oxygen-containing alcohol group. The name levomenol refers to the specific form called (−)-alpha-bisabolol.

Those extra letters and symbols identify the molecule more precisely. You do not need to memorize them, but keep them when comparing a research paper with a laboratory report. A label that simply says “bisabolol” provides less information about the form measured.

Cannabis writing often includes these compounds under the broad heading “terpenes.” Our terpenes versus terpenoids guide explains the chemical distinction without requiring a chemistry background.

Sources: Levomenol chemical record (2026)

What does bisabolol smell like?

Sweet and floral are common descriptions in cannabis references. They are useful aroma words, not a prediction of how someone will feel.

The connection with German chamomile is more than a scent comparison. Original research has identified a chamomile enzyme that produces (−)-alpha-bisabolol. That establishes a chemical connection; it does not make an isolated ingredient, a cup of tea and a cannabis product interchangeable.

Sources: Bisabolol glossary: descriptive aroma (2026); Enantioselective microbial synthesis of (−)-α-bisabolol by a sesquiterpene synthase from chamomile (2014)

Does bisabolol make you relaxed or sleepy?

The studies reviewed here do not establish a reliable relaxing or sleep-inducing effect from bisabolol in cannabis.

A frequently cited 2017 experiment gave bisabolol to mice by injection and measured their behavior in several tests. Researchers reported anxiety-like behavior changes and investigated the involvement of a chemical signaling system called GABA. Higher tested exposures also affected performance on a rotating-rod test used to assess motor function.

This was not a human sleep study or a test of cannabis flower. Our assessment is based on the original abstract. The finding gives researchers a question to investigate, rather than a dependable way to choose a product for relaxation.

Sources: Evidence for the involvement of GABAergic transmission in the anxiolytic-like effect of bisabolol in mice (2017)

What has actually been tested in people?

Two topical studies illustrate why the details matter. Our assessment of both is based on their original abstracts.

The first comparison uses a vehicle—the cream base—as a control. That can help investigate an added ingredient. The second compares different formulations, making attribution harder. Neither establishes how bisabolol-containing cannabis affects someone.

It would be misleading to say there is no human research. It would also be misleading to present these studies as proof of a general health benefit.

Different preparations answer different questions
What was usedWhere it was testedWhat the finding can answer
A cream containing alpha-bisabolol, compared with its base creamPigmented skin in 28 women over eight weeksThe study reported a skin-lightening effect. It addresses that preparation and skin outcome, not sleep, anxiety or cannabis effects.
A spray combining ozonated oil and alpha-bisabolol, compared with a different creamPeople with chronic venous leg ulcers in a 30-day randomized studyThe authors reported improved wound outcomes with the combination. The comparison cannot isolate bisabolol's contribution.

Sources: Whitening effect of alpha-bisabolol in Asian women subjects (2010); Randomized controlled study of ozonated oil and α-bisabolol for chronic venous leg ulcers (2015)

What about pain and inflammation claims?

A 2021 study examined alpha-bisabolol and camphene in laboratory cells and mouse pain models. Researchers studied calcium channels, proteins involved in electrical signaling, and reported reduced pain-related responses under the experimental conditions. The animal experiments delivered the compounds into the space around the spinal cord.

That route is a major limitation when interpreting the result for ordinary cannabis exposure. A biological mechanism can be interesting without demonstrating pain relief from a retail product. The paper provides a basis for further experiments, not a treatment instruction.

Sources: The terpenes camphene and alpha-bisabolol inhibit inflammatory and neuropathic pain via Cav3.2 T-type calcium channels (2021)

Can bisabolol cause a skin allergy?

Contact-allergy reactions have been reported. In one retrospective study, four of seven patients referred with a history of intolerance to a particular moisturizer reacted to both the moisturizer and bisabolol during patch testing. Most of that small referred group had atopic dermatitis.

These were selected patients with a specific concern. The fraction cannot be used to estimate how often bisabolol causes allergy in the general population. It does show why “used in skin care” should not become “cannot cause an allergy.”

Bisabolol is a different substance from linalool or limonene hydroperoxides. Our fragrance contact-allergy guide explains why the exact name on a specialist test report matters; it does not imply that these are the same allergy.

Sources: Compositae-associated allergic contact dermatitis from bisabolol (2011)

What does bisabolol on a cannabis lab report tell you?

It tells you about the reported sample and method. Start with three checks:

A concentration is not a validated relaxation score. Nor does a strain name establish the amount in every batch. Use the terpene-profile guide to work through a report, and the terpene chart to compare botanical descriptions and research questions.

  • Identity: preserve the full compound name, including alpha or other qualifiers.
  • Measurement: read the unit and the laboratory's explanation of non-detects or reporting limits.
  • Sample: match the batch and date before connecting the result to a product.

Sources: Understanding Your Hemp and Cannabis COAs (2020)

Does a completed trial prove that it works?

No. A trial registration describes research; a completed status does not itself supply results.

Two bisabolol studies in ClinicalTrials.gov concern a topical nail treatment and an antihistamine gel. When checked on October 31, 2026, both were marked completed, with no results posted in the registry. That does not mean there is no report elsewhere. It means the registration alone cannot establish effectiveness.

The question to carry into any bisabolol claim is simple: does the evidence match the product, exposure and outcome being discussed?

Sources: Alpha-bisabolol for Onychomycosis Treatment: NCT04940520 (2021); Alpha-Bisabolol Gel With Antihistamine Action: NCT05022108 (2021)